Wednesday, June 10, 2026

pharma Β· Relapsing-Remitting Multiple Sclerosis Β· Spinal Muscular Atrophy

Biogen

Biogen clinical programs β€” 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Intelligence Β· Clinical Programs

Biogen projects

2 ClinicalTrials.gov programs sponsored by Biogen.

Biogen has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Dimethyl fumarate

    Biogen

    Multiple Sclerosis

    approved small molecule completed

    1 trial
  2. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Biogen have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.